healthy volunteers no medical condition
Conditions
Interventions
Trade Name: Erythrocine
Pharmaceutical Form: Powder for solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Trade N
Sponsors
UZLeuven
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy volunteers (18-45 years) who have no bowel symptoms and who are in good general health are eligible for the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • They have relevant underlying disease (cardia, pulmonary, metabolic, kidney or liver disease, …) • They have a history of esophageal or gastric surgery, or recurrent or intermittent upper gastrointestinal symptoms (upper abdominal pain, nausea, vomiting, bothersome fullness or early satiation, heartburn, regurgitation,…) • They have a history of allergy to several types of drugs or food. • They have ever been treated for depression • There is a possibility of becoming pregnant during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: We set out to investigate whether IGP is a determinant of satiation. To this end we plan to investigate whether: 1) sumatriptan reduces IGP during food intake and which effect this has on satiation (protocol 2: sumatriptan study) 2) erythromycine increases IGP during food intake and which effect his has on satiation (protocol 3: erythromycin study) ;Secondary Objective: none;Primary end point(s): liquid nutrient tolerance to reach maximum satiation | — |
Countries
Belgium
Outcome results
None listed